NE
NeoGenomics, Inc.
NEO · NASDAQ
$19.41 -1.87% (-$0.37)
1M +18.28%
Market Cap $498.7M
P/E Ratio -
Div. Yield -
ROE 6.31%
Bulios Fair Price
$12.83
33.9% downside
Current Price
$19.41
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NEO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
44 /100
Fair P/S 0.65x
P/B 0.63x
EV/EBITDA 62.20x
Growth
60 /100
Stable Book val. growth 5.71%
Rev. growth 12.58%
FCF growth N/A
Profitability
17 /100
Weak Net margin 6.77%
Op. margin 8.63%
FCF margin 0.96%
Quality
7 /100
Poor ROE 6.31%
ROA 3.84%
Asset turnover 0.57x
Debt
38 /100
Moderate Current ratio 3.60x
Int. coverage -20.37x
Net debt/EBITDA 23.50x
Stability
50 /100
Moderate Rev. volatility 3.10%
EPS volatility 37.95%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NEO
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Anthony Zook
Employees
2,500
Headquarters
Fort Myers
Upcoming events
27 OCT
Earnings
Upcoming earnings report